

March 2, 2017

## PDL BioPharma to Present at Two Upcoming Investor Conferences

INCLINE VILLAGE, Nev., March 2, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in March.

Cowen and Company 37<sup>th</sup> Annual Health Care Conference Wednesday, March 8, 2017, 8:00 a.m. EST Boston, MA

## 29<sup>th</sup> Annual ROTH Conference Tuesday, March 14, 2017, 12:00 p.m. PDT Orange County, CA

To access the live and subsequently archived webcast of the presentation, go to the company's website at <a href="http://www.pdl.com">http://www.pdl.com</a> and go to "Presentations and Events." Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The archived webcast will be available for at least seven days following the presentation.

## About PDL BioPharma

PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In late 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities and in 2016, began making equity investments in commercial stage companies, the first being Noden Pharma DAC. PDL has committed over \$1.4 billion and funded approximately \$1.1 billion in these investments to date. PDL is headquartered in Incline Village, Nevada.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Logo - http://photos.prnewswire.com/prnh/20110822/SF55808LOGO

To view the original version on PR Newswire, visit: <a href="http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-two-upcoming-investor-conferences-300416626.html">http://www.prnewswire.com/news-releases/pdl-biopharma-to-present-at-two-upcoming-investor-conferences-300416626.html</a>

SOURCE PDL BioPharma, Inc.

News Provided by Acquire Media